Literature DB >> 26807249

Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region.

Abdul Rahman Jazieh1, Hasan Jaafar2, Mohammed Jaloudi2, Rasha Saleh Mustafa3, Kakil Rasul4, Jamal Zekri5, Hanaa Bamefleh1, Ahmed Gasmelseed1.   

Abstract

The aim of the present study was to determine the prevalence of epidermal growth factor receptor mutations (EGFRmut) in the Gulf region (GR) and its correlation with demographic and clinical characteristics. A multisite retrospective study was conducted, including institutions from Saudi Arabia, the United Arab Emirates and Qatar. All consecutive patients with non-small-cell lung cancer tested for EGFRmut were eligible. Data collected included demographic information, disease characteristics and EGFR test results. Data on 230 patients were obtained. The median age of the patients was 61 years (range, 26-87 years); 169 patients (69.83%) were male and 204 (88.7%) were Arab. The histological subtype was adenocarcinoma in 191 (83.4%) and squamous cell carcinoma in 21 cases (9.17%). Overall, EGFRmut were detected in 66 patients (28.7%), with a prevalence of 32.46% in adenocarcinoma. No squamous cell carcinomas were found to harbor EGFRmut. The univariate and multivariate analyses revealed that female gender, non-smoking status and adenocarcinoma subtype were significant predictors for EGFRmut. There was no difference between Arabs and non-Arabs. In conclusion, to the best of our knowledge, this is the first multisite study to report the prevalence of EGFRmut in the GR population, which was found to be higher compared with that in Western, but lower compared with that in Far Eastern populations. Studies evaluating the efficacy of targeted therapy in this population are underway.

Entities:  

Keywords:  Gulf region; epidermal growth factor receptor; non-small-cell lung cancer

Year:  2015        PMID: 26807249      PMCID: PMC4665377          DOI: 10.3892/mco.2015.644

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  12 in total

1.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.

Authors:  Najla Fakhruddin; Rami Mahfouz; Fadi Farhat; Arafat Tfayli; Rabab Abdelkhalik; Mark Jabbour; Lamis Yehia; Ziyad Mahfoud; Ghazi Zaatari
Journal:  Oncol Rep       Date:  2014-08-14       Impact factor: 3.906

3.  Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.

Authors:  Makoto Sonobe; Masashi Kobayashi; Masashi Ishikawa; Ryutaro Kikuchi; Ei Nakayama; Tsuyoshi Takahashi; Toshi Menju; Kazumasa Takenaka; Ryo Miyahara; Cheng-Long Huang; Kenichi Okubo; Toru Bando; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2011-05-24       Impact factor: 5.344

Review 4.  A translational view of the molecular pathogenesis of lung cancer.

Authors:  Mitsuo Sato; David S Shames; Adi F Gazdar; John D Minna
Journal:  J Thorac Oncol       Date:  2007-04       Impact factor: 15.609

5.  United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Authors:  Martin H Cohen; Grant A Williams; Rajeshwari Sridhara; Gang Chen; W David McGuinn; David Morse; Sophia Abraham; Atiqur Rahman; Chenyi Liang; Richard Lostritto; Amy Baird; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

6.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

8.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

9.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

10.  Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma.

Authors:  Hassan Errihani; Hanane Inrhaoun; Anouar Boukir; Fouad Kettani; Lamia Gamra; Amina Mestari; Lamia Jabri; Youssef Bensouda; Hind Mrabti; Ibrahim Elghissassi
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

View more
  7 in total

1.  The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).

Authors:  Hanan H Ramadhan; Dhuha F Taaban; Jubran K Hassan
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

2.  EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.

Authors:  Zineb Benbrahim; Teresita Antonia; Nawfel Mellas
Journal:  BMC Cancer       Date:  2018-09-14       Impact factor: 4.430

3.  Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer.

Authors:  Mohamed Lahmadi; Leila Beddar; Amira Lyna Rouibah; Ali Boumegoura; Houda Boufendi; Asma Temim; Anissa Nini; Feriel Sellam; Dalila Satta
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

4.  Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon.

Authors:  Ghina Fakhri; Reem Akel; Ibrahim Khalifeh; Hassan Chami; Adel Hajj Ali; Majd Al Assaad; Haneen Atwi; Humam Kadara; Arafat Tfayli
Journal:  SAGE Open Med       Date:  2021-09-08

5.  Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017.

Authors:  Sara H AlQahtani; Areeb M AlOgaiel; Kowthar N AlMosa; Suha H Alenazi; Monira K AlHasan; Reham H AlObaidan; Bayan D Aldokheel; Khalid AlSaleh; Maha Arafah; Imran Ali Khan; Maram AlOtaiby
Journal:  Cureus       Date:  2021-11-22

6.  Saudi lung cancer management guidelines 2017.

Authors:  Abdul Rahman Jazieh; Khaled Al Kattan; Ahmed Bamousa; Ashwaq Al Olayan; Ahmed Abdelwarith; Jawaher Ansari; Abdullah Al Twairqi; Turki Al Fayea; Khalid Al Saleh; Hamed Al Husaini; Nafisa Abdelhafiez; Mervat Mahrous; Medhat Faris; Ameen Al Omair; Adnan Hebshi; Salem Al Shehri; Foad Al Dayel; Hanaa Bamefleh; Walid Khalbuss; Sarah Al Ghanem; Shukri Loutfi; Azzam Khankan; Meshael Al Rujaib; Majed Al Ghamdi; Nagwa Ibrahim; Abdulmonem Swied; Mohammad Al Kayait; Marie Datario
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219

7.  Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer.

Authors:  Jeong-Oh Kim; Jung-Young Shin; Seo Ree Kim; Kab Soo Shin; Joori Kim; Min-Young Kim; Mi-Ran Lee; Yonggoo Kim; Myungshin Kim; Sook Hee Hong; Jin Hyoung Kang
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.